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Objective: To evaluate the carriage prevalence, serotype distribution, and antibiotic resistance for pneu-
mococcal carriage isolates collected 4–8 years after introduction of pneumococcal conjugate vaccines
(PCVs) in Stockholm, Sweden, and to identify risk factors for carriage and calculate the invasive disease
potential for emerging serotypes.
Methods: Nasopharyngeal aspirates were collected from 3024 children aged 0–<5 years at regular visits
at 23 Child Health Centers in Stockholm County in 2011–2015, and from 787 parents in 2014–2015. The
invasive disease potential was calculated for serotypes using invasive disease isolates from 824 patients
of all ages identified in the Stockholm County during the same time period as the carriage isolates.
Results: A total carriage prevalence of 30% did not change during the study period. Non-vaccine types
(NVT) dominated (94% by 2015) and the most common serotypes in descending order were 11A, 23B,
35F and 21. Risk factors for carriage were: age P3 months–<3 years, having siblings, attending day-
care and having travelled abroad the last 3 months. Antibiotic resistance remained low. The invasive
disease potential was high for NVT 8, 9N, 12F, and 22F, while low for a majority of emerging NVTs in car-
riage.
Conclusion: The carriage prevalence remained the same 4–8 years after vaccine introduction, but sero-
type replacement became almost complete. A majority of emerging NVTs in carriage showed a low inva-
sive disease potential. Carriage studies are an important complement to invasive disease surveillance to
understand the full effect of PCV vaccine programs.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Streptococcus pneumoniae causes severe infections mainly in
young children and the elderly. Mortality and complication rates
are high in invasive pneumococcal disease (IPD), such as
septicemia and meningitis, and morbidity in the more commonnon-invasive pneumococcal diseases such as pneumonia, sinusitis
and otitis media, is significant. Pneumococci are frequently found
colonizing the nasopharynx of healthy young children, from where
the bacteria may spread and cause disease [1,2]. Asymptomatic
nasopharyngeal carriage is the reservoir for pneumococci and mir-
rors circulating isolates causing disease. It has been suggested that
studies of carriage could be an alternative and easier way to study
the effect of vaccination [3,4]. However, since it is important to
know whether post-vaccination emerging types cause disease,
we need to perform simultaneous studies on nasopharyngeal car-
riage and invasive disease, within the same area and time [5,6],
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types [7–10].
Pneumococcal conjugate vaccine (PCV), effective against 7, 10
or 13 of the 97 serotypes described so far, was first introduced in
the US year 2000, and is now used in over 125 countries world-
wide [11]. In several studies PCV has been shown to be effective
in vaccinated children against IPD, pneumonia, sinusitis and otitis
media, caused by the serotypes included in the vaccine and may
also provide some cross protection between strains in the same
serogroup [12–17]. Protection with PCV is partly mediated by
mucosal immunity, which therefore might affect colonization
[18]. Reduced carriage of vaccine-types (VT) in young children
has also been shown to lead to a herd immunity effect in older chil-
dren and adults in some studies [19–21]. Importantly, when PCV-
serotypes decrease, the biological niche in the nasopharynx will be
filled with non-vaccine types (NVTs), so called serotype replace-
ment, and in some, but not all studies, an increase of other bacte-
rial species, such as S. aureus or Moraxella spp. has been described
[19–23]. Clinical invasive disease patterns may change and
increased antibiotic resistance has been observed [24–26], which
underlines the importance to study both IPD and carriage in order
to foresee new disease patterns and adapt treatment policies.
PCV was implemented in Stockholm County, Sweden, as part of
the child vaccination schedule, at age 3, 5 and 12 months, for chil-
dren born from 1st of July 2007. PCV7 was changed to PCV13 in
January 2010. PCV vaccination coverage with three doses in
2-year old children increased to 97% within 2 years of the start of
the program, and has been stable at this level since then [27].
Recently we showed the effects of vaccine introduction on IPD
and carriage, during a ten-year period in Stockholm County [28].
In the current study, we performed an in-depth analysis of carriage
data from 2011 to 2015. The aim was to evaluate nasopharyngeal
pneumococcal carriage prevalence, serotype distribution, antibi-
otic resistance and clinical risk factors for carriage in children aged
0–<5 years that attended regular Child Health Center visits, four to
eight years after implementation of PCV in the child vaccination
schedule in Stockholm County. Furthermore, we calculated the
invasive disease potential for emerging serotypes in carriage by
comparing the carriage data with IPD data from Stockholm County
collected during the same time period.2. Methods
2.1. Study design and population
This was a prospective study with samples obtained from the
23 largest Child Health Centers, geographically well distributed
in Stockholm County, from 5 August 2011 to 30 May 2015. The
research team stayed one week at each center and included chil-
dren on a consecutive basis, after their regular child health visits.
During February 2014 to May 2015, parents of included children
were also invited to participate.
Data on pneumococcal serotypes causing IPD was collected
from the national mandatory surveillance system at the Public
Health Agency of Sweden for the same time period Stockholm
County, as previously described [28]. Because of few IPD cases in
children aged 0–<5 years (n = 20) we included IPD isolates from
all age groups, in order to have a comparable number of IPD and
carriage strains, as has been done in a previous study [9].2.2. Data collection
Nasopharyngeal aspirates were collected once from each partic-
ipant except if there were more than one month between two sam-
ples. If both samples carried pneumococci, theywere defined as twoseparate carriers. Aspirates were discharged in 3 ml of NaCl and
divided into three different tubes kept at 5–8 C and also streaked
onto blood and chocolate agar plates within 8 h after sampling.
Information of the participants was gathered by a structured
questionnaire in an interview with the care-givers including his-
tory of illness and treatment, possible risk factors for carriage
and socio-demographic data.
2.3. Strain isolation and serotyping
Pneumococcal isolates were identified according to standard
procedures at the department of Clinical microbiology, Karolinska
University hospital. Serotyping was performed at the Public Health
Agency of Sweden using gel diffusion and/or Quellung reactions as
previously described [29].
2.4. Antimicrobial susceptibility
Antibiotic susceptibility was tested for erythromycin, and clin-
damycin using discs and for penicillin G using E-test as described
elsewhere [30]. Species-related breakpoints (non-meningitis) were
used according to the SRGA/EUCAST (http://www.eucast.org).
2.5. Statistical analysis
Fisher’s exact test was used to compare variables between dif-
ferent groups (carriers/non-carriers and VT/NVT). VT was defined
as the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F
and 23F) included in PCV13. In order to study trends in antibiotic
resistance and changes in proportion of individual serotypes over
time, univariate logistic regression was performed. Invasive dis-
ease potential was calculated for each serotype, using the following
formula for the serotype specific odds ratio: OR = [ad]/[bc], where a
was the number of invasive X isolates, b was the number of car-
riage X isolates, c was the number of invasive non-X isolates, and
d the number of carriage non-X isolates. An OR of >1 with its
95% confidence interval not including 1 indicated a high invasive
disease potential, with Holm’s method used to adjust for the mul-
tiple comparisons [8]. Serotype diversity was measured with the
Simpson index of diversity and the corresponding confidence inter-
vals were calculated as described earlier [31]. Finally, a multivari-
ate logistic regression was performed to estimate the association of
the variables with carriage, after adjusting for confounding. The
statistical software R, version 3.2.2 (http://www.r-project-org/)
was used for the analyses and a two sided p-value less than 0.05
was considered to be statistically significant.
2.6. Ethical considerations
Ethical approval was obtained from the Stockholm Regional
Ethics Committee. Parents signed a consent form before data
collection.
3. Results
3.1. Carriage prevalence remained the same post-PCV introduction
In total, 3024 healthy children less than 5 years old were sam-
pled. Of these 907(30%) were colonized with S. pneumoniae. Car-
riage prevalence remained stable during 2011–2015; 31.1%,
29.6%, 29.3%, 30.6%, and 30.7%, respectively for the years. Seven
of the 18 children that were sampled twice with at least one month
apart carried pneumococci. Two of these children carried pneumo-
cocci in both samples, whereof one carried different serotypes.
Nine children had two serotypes isolated from the same aspirate.
Table 1
Carriage prevalence, proportion of vaccine types (VTs) and non-vaccine types (NVTs) in carriage as well as the Simpson index of diversity for serotypes.
Children 2011 2012 2013 2014 2015 Total
Number of children included 328 975 832 638 251 3024
Children colonized with
pneumococci N (%)
102(31.1) 289(29.6) 244(29.3) 195(30.6) 77(30.7) 907(30.0)
Colonized children with
NVTs N (%)
87(85.3) 251(86.9) 216(88.5) 177(90.8) 72(93.5) 803(88.5)
Simpson index of diversity
(95%CI)a
0.906(0.874–0.939) 0.922(0.909–0.935) 0.939(0.930–0.948) 0.939(0.928–0.949) 0.940(0.925–0.956) NA
Parents – – – 2014 2015 Total
Number of parents included NA NA NA 526 261 787
Parents colonized with
pneumococci N (%)
NA NA NA 13(2.5) 14(5.3) 27(3.4)
Parents colonized with
NVTs N (%)
NA NA NA 10(76.9) 12(85.7) 22(81.5)
a Comparison of Simpson index 2015 vs 2011: p-value = 0.06, ref: Galanis et al. [28].
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parents included, 27(3.4%) were colonized with pneumococci, of
which the most commonly isolated serotypes were 10A, 11A,
23A and 35F (Table 1). In 13/27(48%) of the adult carriers, parents
and children carried the same serotype.
A majority of the children were <1 year (N = 2251, 74%), since
most regular visits at the Child Health Centers are scheduled for
this age group. Carriers of pneumococci were slightly older
(0.97 years) than non-carriers (0.77 years) (p < 0.001). Most chil-
dren in Sweden start day-care between 12 and 18 months of age.
Thus, only 12% of the included children attended regular day-
care, but 32% attended open day-care facilities, where parents
meet other parents and their children. In total, 52% of the partici-
pants were boys and 48% girls (Table 2). Seventeen percent of
the children (N = 517) had travelled abroad in the last three
months and 45 of those had travelled twice and 6 three times. Of
all the trips, 22% went to Nordic countries, 57% travelled within
the rest of Europe and 21% went outside Europe. At least one dose
of PCV had been given to 9.7% of children aged 0–<3 months, 95.2%
of children 3–<6 months, 99.6% of children 6–<9 months, 99.4% to
children 9–<12 months, 99.2% in 1–<2 year olds, 100% in 2–<3 year
olds and 93.1% in 3–<5 year olds. 91% of the children >1 year had
received three doses of PCV.Table 2
Characteristics of participants and risk factors for pneumococcal carriage in children <5 ye
Total
(N = 3024)
No (%)
Carrier
(N = 907)
No (%)
Non carri
(N = 2117
No (%)
Age 0–<3 months 547(18) 77(8.5) 470(22)
3–<6 months 794(26) 205(23) 589(28)
6–<9 months 556(18) 179(20) 377(18)
9 months–<1 year 354(12) 135(15) 219(10)
1–<2 years 537(18) 228(25) 309(15)
2–<3 years 62(2) 28(3.1) 34(1.6)
3–<5 years 174(6) 55(6.1) 119(5.6)
Sex (Girls) 1455(48) 450(50) 1005(48)
Day-care attendance 374(12) 152(17) 222(11)
Open day-care attendance 962(32) 324(36) 638(30)
Antibiotic consumption (current) 27(0.9) 9(1.0) 18(0.8)
Antibiotic consumption (last 12
months)
399(13) 147(16) 252(12)
Anyone smoking at home 320(11) 96(11) 224(11)
Child with chronic diseases 64(2.1) 26(2.9) 38(1.8)
Travelled abroad last 3 months 517(17) 194(21) 323(15)
Siblings 1851(61) 751(83) 1100(52)
Hospitalized the last 3 months 100(3) 24(2.6) 76(3.6)
Breastfeeding 1628(54) 432(48) 1196(57)
Mother’s highest education elementary
school
147(4.9) 47(5.2) 100(4.7)
Father’s highest education elementary
school
163(5.4) 53(5.9) 110(5.3)3.2. Risk factors for pneumococcal carriage
Among the children, the following factors were significantly
more common in pneumococcal carriers: age groups older than
3 months, attending day care or open day-care, antibiotic use dur-
ing the last year, having travelled abroad in the last three months,
not breastfeeding, and having siblings (Table 2). None of these fac-
tors differed significantly between children carrying vaccine-types
(VTs) compared to non-vaccine types (NVTs).
In the multivariate analysis, the following risk factors for car-
riage remained significant: age groups 3 months to 3 years (com-
pared to <3 months), siblings in the family, attending day-care
and open day–care, and travelled abroad the last 3 months
(Table 3).
3.3. Non-vaccine types dominated in carriage and the serotype
diversity increased during the study years
During the study period, a total of 36 serotypes were identified
(Fig. 1). The most common serotypes in children, all NVTs, were in
descending order: 11A, 23B, 35F, 21, 15 B and 15C. Overall, the pro-
portion of NVTs increased from 85% in 2011 to 94% in 2015
(Table 1) (p = 0.04). Three NVTs changed significantly in carriagears.
er
)
p value Vaccine types
(N = 83)
No (%)
Non-vaccine types
(N = 824)
No (%)
p
value
Reference 6(7.2) 71(8.6) –
<0.001 21(25) 184(22) 0.65
<0.001 15(18) 164(20) 1
<0.001 13(16) 122(15) 0.8
<0.001 20(24) 208(25) 1
<0.001 0(0) 28(3.4) 0.19
<0.001 8(9.6) 47(5.7) 0.26
0.3 40(48) 410(50) 0.82
<0.001 14(17) 138(17) 1
<0.001 28(34) 296(36) 0.72
0.68 0(0) 9(1.1) 1
<0.001 9(11) 138(17) 0.21
1 10(12) 86(10.4) 0.58
0.07 2(2.4) 24(2.9) 1
<0.001 14(17) 180(22) 0.33
<0.001 65(78) 686(83) 0.28
0.22 1(1.2) 23(2.8) 0.72
<0.001 42(51) 390(47) 0.64
0.64 5(6.0) 42(5.1) 0.61
0.48 5(6.2) 48(5.9) 0.81
Table 4
Antibiotic resistance of colonizing pneumococcal strains N = 916.
2011
(N = 102)
No (%)
2012
(N = 289)
No (%)
2013
(N = 244)
No (%)
2014
(N = 195)
No (%)
2015
(N = 77)
No (%)
PCG-I* 5(5.9) 22(8.2) 21(11.1) 10(7.6) 4(5.4)
PCG-R 0(0) 0(0) 0(0) 0(0) 1(1.4)
ERY-R+I** 2(2.0) 9(3.1) 11(4.5) 8(4.1) 5(6.6)
CLI-R*** 1(1.0) 6(2.1) 6(2.5) 5(2.6) 2(2.6)
I = intermediate resistance and R = resistant.
* Test for Trend in Proportions in PCG-I: p-value = 0.93.
** Test for Trend in Proportions in ERY-R+I: p-value = 0.1.
*** Test for Trend in Proportions in CLI-R: p-value = 0.4.
Fig. 1. Serotype distribution among nasopharyngeal pneumococcal isolates (N = 916) fro
cases of double carriage, the number of carriers is not the same as the number of isolate
Table 3
Risk factors for pneumococcal carriage when controlling for multiple factors in a
logistic regression model.
OR (95% CI)*
Age (reference 0–<3 months) Ref
3–<6 months 2.3(1.7–3.1)
6–<9 months 3.0(2.1–4.2)
9 months–<1 year 3.9(2.6–5.7)
1–<2 years 4.5(3.0–6.6)
2–<3 years 3.3(1.7–6.6)
3–<5 years 1.7(1.0–3.1)
Sex girl Ref
Sex boy 0.9(0.8–1.1)
No antibiotic use (current or in the last year) Ref
Number of antibiotic treatments last year: 1 0.8(0.6–1.1)
Number of antibiotic treatments last year: >2 1.2(0.7–1.9)
No current antibiotic use Ref
Using antibiotics currently 0.7(0.3–1.9)
Number of children at home 1 child Ref
Number of children at home: 2 4.8(3.9–6.0)
Number of children at home: 3 5.5(4.3–7.1)
Not attending day care Ref
Attending day-care center 1.4(1.0–2.1)
Not attending open day care Ref
Attending open day-care 1.3(1.1–1.6)
No chronic illness Ref
Chronic illness 1.2(0.6–2.0)
Not hospitalized last 3 months Ref
Hospitalized last 3 months 1.1(0.7–1.8)
None smoking at home Ref
Anyone smoking at home 1.0(0.72–1.3)
Highest education: elementary school Ref
Mother’s highest education: high school 1.1(0.7–1.6)
Mother’s highest education: university 1.1(0.7–1.7)
Father’s highest education: high school 0.8(0.6–1.2)
Father’s highest education: university 0.9(0.6–1.3)
Not travelled abroad last year Ref
Travelled abroad last year 1.3(1.0–1.6)
* Bold means significant at p < 0.05.
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from 7.6% to 3.6% (p = 0.003), 23B increased from 0.3% to 3.6%
(p < 0.001) and 35B increased from 0.6% to 2.0% (p = 0.02). Serotype
19A was among the most prevalent VTs in 2011, but decreased in
total carriage prevalence from 2.1% to 0% (p = 0.02) during the
study period. None of the other VTs changed significantly. To study
whether the diversity of serotypes changed during the time period,
the Simpsons index for diversity was calculated and a slight, but
non-significant, increase was observed (Table 1).3.4. No change in antibiotic resistance was observed during the study
period
Antibiotic resistance was low for the antibiotics tested, peni-
cillin G (PCG), erythromycin (ERY) and clindamycin (CLI) (Table 4).
There was no change in the proportion of isolates with decreased
susceptibility against PCG (p = 0.93), ERY (p = 0.1) or CLI (p = 0.4).m healthy children 0–<5 years (N = 907)⁄ in Stockholm during 2011–2015⁄⁄. *Due to
s. **PCV7 = PCV7 serotypes, PCV10 = PCV10 serotypes and PCV13 = PCV13 serotypes.
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but high for serotype 22F
The invasive disease potential was calculated for individual ser-
otypes using data on patients of all ages with IPD in Stockholm
during the years 2011–2015 (N = 824), i.e. the same time period
as for the carriage data from children less than 5 years. Of the
824 IPD cases only 20(2.4%) occurred in children aged less than five
years. A high invasive disease potential was found for VTs 1, 3, 4
and 7F, and NVTs 8, 9N, 12F and 22F. The most common NVTs,
11A, 23B and 35F, all had a lower invasive disease potentials
(OR < 1) (Table 5), which was also the case in total for 66% of all
the NVTs (525/799).4. Discussion
In this prospective pneumococcal carriage study we examined
the effects of PCV7, and subsequently PCV13 use, on serotype dis-
tribution, antibiotic resistance and the invasive disease potential
for emerging serotypes, in young healthy children in Stockholm
County during 2011–2015, i.e. up to eight years after vaccine
introduction.
The major shift from VTs to NVTs post-PCV in Stockholm, with
high vaccination coverage and without catch-up vaccination, was
established already four years after PCV introduction [28]. The pro-
portion of NVTs continued to increase during the study period and
in 2015 94% of the pneumococcal isolates were of NVTs. The major
risk factors for carriage were age 3 months to 3 years, havingTable 5
OR for invasive disease potential of serotypes in IPD (all ages) and carriage (children
<5 years), 2011–2015.
Invasive disease
N = 824
Carriage
N = 916
OR(95%CI)#
3** 117 8 18.8(9.1–44.7)
22F 95 28 4.1(2.7–6.6)
7F** 57 1 67.9(11.6–2697)
19A** 47 32 1.7(1–2.7)
9N 39 4 11.3(4.1–43.8)
33F 38 36 1.2(0.7–1.9)
23A 36 62 0.6(0.4–1)
11A 34 139 0.2(0.2–0.4)
8 33 1 38.1(6.4–1543)
10A 32 31 1.2(0.7–2)
Other 30 18 1.9(1–3.6)
35F 22 88 0.3(0.2–0.4)
23B 20 66 0.3(0.2–0.5)
6C 20 39 0.6(0.3,1)
16F 20 24 0.9(0.5–1.8)
1** 19 0 1(5.3–1)
4* 17 0 1 (4.7–1)
15B 16 59 0.3(0.2–0.5)
15A 16 17 1(0.5–2.2)
6A** 15 6 2.8(1–8.9)
15C 12 50 0.3(0.1–0.5)
6B* 12 6 2.2(0.8–7.3)
35B 11 45 0.3(0.1–0.5)
9V* 11 0 1 (2.8–1)
19F* 10 20 0.6(0.2–1.2)
31 10 8 1.4(0.5–4.1)
12F 10 0 1(2.5–1)
38 9 13 0.8(0.3–2)
23F* 9 7 1.4(0.5–4.6)
17F 5 11 0.5(0.1–1.6)
21 1 78 0(0–0.1)
NT 1 19 0.1(0–0.4)
# Significant OR and 95% CI in bold. Serotypes with significant OR > 1 have an
increased risk for causing invasive disease.
* Included in PCV7.
** Included in PCV13.siblings, attending day-care and open day-care, and having trav-
elled abroad within the last 3 months.
A major strength of this study is the large sample size of both
colonizing and IPD isolates over 4 consecutive years collected in
the same county. Since 99% of all children in Stockholm attend
Child Health Centers and the centers included were purposely
selected to represent all geographic areas of the county, we believe
that the study represent the child population in the Stockholm
region [32]. However, the proportion of parents to participating
children with only elementary school as the highest educational
level was lower among those who consented to participate (5%),
compared to the general population in Stockholm County (11%)
according to Statistics Sweden (www.scb.se). This may indicate
that participating families had a somewhat higher socioeconomic
level than those not participating, but there was no association
between carriage prevalence and educational levels of the parents.
A serotype replacement, with a high proportion of NVTs, was
prominent already at the start of the study, NVTs continued to
expand over the four study years and the serotype diversity
increased (Table 1). This is in accordance with several randomized
trials and surveillance studies after PCV7/PCV13 introduction, such
as in England and the Netherlands [6,33–38]. In a study from Por-
tugal, however, where the coverage with at least one PCV dose
increased from 76% to 84% during 2008–09, no change was
observed in the proportion of NVTs in children <7 years in day-
care centers [39]. 19F persisted in carriage, but other VTs such as
6B, 23F and 14 decreased. In our study 19F, together with 19A,
were the most frequently isolated VTs in carriage in 2011, however
neither 19A nor 19F was isolated in carriage during 2015, indicat-
ing that several years of high coverage was needed before these VT
disappeared in carriage. The total carriage prevalence of the VT ser-
otypes 3 and 23F increased non-significantly in carriage (p = 0.5
and p = 0.77 respectively) from 2011 to 2015 [28].
How pneumococcal carriage, antibiotic resistance and disease
pattern changes after PCV implementation depend on several fac-
tors, e.g. vaccine coverage, the socio-economic situation, hygiene,
day-care attendance, and use of antibiotics. The vaccination cover-
age has been high in Sweden since PCV was introduced, and more
than 80% of children start day-care attendance after 12 months of
age. We found that antibiotic resistance rates were low and there
were no increasing trends. This is in agreement with some studies
[40], but in other countries antibiotic resistance rates have
increased both to macrolides and penicillin G mainly post-PCV7
due to expansion of 19A [41,42]. Yet other studies have observed
a decline in antibiotic resistance rates especially post-PCV13, also
covering 19A [43,44]. In Sweden we have a low antibiotic usage,
strong hospital hygiene policies and national incentive programs
to further decrease antibiotic usage and surveillance of antibiotic
resistance [45], all factors that may contribute to lowering the
resistance rates. Therefore, direct effects of PCV on antibiotic resis-
tance might be difficult to measure in Sweden.
WHO have made recommendations for standard methods for
measuring nasopharyngeal carriage of pneumococci [46,47]. In
our study we used nasopharyngeal aspirates instead of the recom-
mended swabs, because we found it less painful for the participat-
ing children. Importantly, WHO states that aspirates are acceptable
since they have the same, or even higher, sensitivity for pneumo-
coccal detection. Also, our carriage prevalence was similar to
equivalent studies in Europe [37,48].
The duration of carriage differs with serotype [49] and some
serotypes are mainly found causing invasive disease, i.e. have a
high invasive disease potential, such as serotypes 1 and 7F
[7,9,50]. Other serotypes are mainly found in carriage and hence
have been shown to have a low invasive disease potential. This is
in agreement with our data, although we recognize the limitation
of comparing carriage isolates from children with invasive isolates
4570 A. Lindstrand et al. / Vaccine 34 (2016) 4565–4571from all age groups. An important finding was that a majority of
new emerging NVTs in carriage had a low invasive disease poten-
tial. Overall, the invasive disease potential was lower for dominat-
ing NVTs (11A, 35F, 21, 23B) in carriage post-PCV as compared to
VTs in carriage before PCV, suggesting that carriage strains post-
PCV would be less prone to cause invasive disease. Scott et.al com-
pared the invasive disease potential pre- and post-PCV7 in Alaskan
children 12 years after PCV introduction, and did not detect any
significant change for individual serotypes as measured by invasive
rate ratios [5]. However, we found that some emerging NVTs, 8, 9N,
12F, and 22F, showed a high invasive disease potential. These NVTs
were all among the top ten serotypes causing invasive disease in all
ages in Stockholm during this time period. Interestingly in the UK,
22F was reported to have a low invasive disease potential before
PCV, which increased after PCV [6,9,10]. An explanation for this
could be that 22F changed its genetic composition through for
example capsular switch events. The continued evolution of pneu-
mococci to escape external threats like PCV and antibiotics war-
rants for a continued close surveillance of both pneumococcal
carriage and IPD. It is evident that an equilibrium of new VTs ver-
sus NVTs is still not obtained in our context and future vaccine
policies need to consider including NVTs such as serotypes 22F,
9N and 8 in waiting for novel serotype independent approaches.
In conclusion, this study shows serotype replacement with an
emergence of NVTs with mainly low invasive disease potential
eight years after introduction of PCV7, and 4 years after PCV13.
Surveillance of both carriage and invasive disease is important to
understand the full effect of the pneumococcal conjugate vaccine
program, and to identify possible needs for other vaccine
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